<DOC>
	<DOCNO>NCT01651390</DOCNO>
	<brief_summary>To determine randomize controlled trial ( RCT ) whether percutaneous coronary intervention - patient in-stent restenosis either bare metal stent drug elute stent - Pantera Lux balloon angiographically non-inferior percutaneous intervention Orsiro stent 6 month post-procedure .</brief_summary>
	<brief_title>Clinical Performance Pantera Lux Balloon Versus Orsiro Stent Patients With In-stent Restenosis .</brief_title>
	<detailed_description>This clinical investigation international , multi-center , randomize control trial angiographic follow 6 month . Clinical follow ups take place 6 , 12 18 month . Up 210 subject block randomize 2:1 receive Pantera Lux balloon Orsiro stent stratify accord diabetic status screening .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Subject provide write informed consent 2 . Subject ≥ 18 year 3 . Clinical evidence ischemic heart disease and/or positive functional study , stable unstable angina pectoris document silent ischemia 4 . Subject eligible percutaneous coronary intervention 5 . Subject acceptable candidate coronary artery bypass surgery 6 . Subject instent restenotic lesion* either bare metal stent drug elute stent ( Mehran class I , II , III , IV Mehran et al . Circulation 199 ; 100 : 18721878 ) . *Target lesion 7 . Subjects maximum 2 target lesion . In case 2 target lesion , lesion must either bare metal stent drug elute stent , must treat session type device per randomization outcome , e.g . drug elute stent . 8 . Target reference vessel diameter ( visual estimation ) : ≥ 2.0 ≤ 4.0 mm 9 . Target lesion length ( visual estimation ) : ≥ 6.0 ≤ 28.0 mm 10 . Target lesion stenosis ( visual estimation ) : &gt; 50 % ≤ 100 % 11 . Target lesion native coronary artery 1 . Planned ( stag ) interventional treatment vessel ( ) target lesion ( ) within 30 day pre and/or post BIOLUX RCT index procedure . 2 . Evidence acute STsegmentelevation myocardial infarction within 48 hour prior index procedure accord universal definition myocardial infarction 3 . Subjects acute cardiac decompensation acute cardiogenic shock 4 . Subject life expectancy le 18 month 5 . In investigator opinion subject able comply follow requirement 6 . Impaired renal function ( excluded subject need dialysis subject creatinine level ≥ 221 µmol per liter ( 2.5 mg per deciliter ) within 72 hour intend treatment ) 7 . Thrombus target vessel 8 . Target lesion locate leave main coronary artery 9 . Documented leave ventricular ejection fraction ( LVEF ) ≤ 30 % 10 . Known allergy : acetylsalicylic acid , clopidogrel , prasugrel , ticagrelor , heparin , contrast medium , sirolimus similar drug ( i.e. , ABT 578 , biolimus , tacrolimus ) ; CoCr , PLLA , silicon carbide 11 . Subject receive oral intravenous immunosuppressive therapy ( e.g. , inhaled steroid exclude ) know lifelimiting immunosuppressive autoimmune disease ( e.g. , human immunodeficiency virus , systemic lupus erythematosus , include diabetes mellitus ) 12 . Subject currently enrol investigational device drug trial primary endpoint reach 13 . Pregnant and/or breastfeed female female intend become pregnant time study 14 . Previously enrol trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Restenosis</keyword>
	<keyword>Drug coat balloon</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Sirolimus</keyword>
</DOC>